Anika Therapeutics (NSDQ:ANIK) announced this month that CEO Charles Sherwood plans to retire after working for Anika for nearly twenty years. Joseph Darling, who has been Anika’s president since July 2017, will take his place in the corner office. Darling has previously served in executive leadership roles across an array of medtech companies like Abbott (NYSE:ABT), Baxter (NYSE:BAX) […]
BioTime lands $2m for dry-AMD therapy
BioTime Inc. (NYSE:BTX) said today that its subsidiary, Cell Cure Neurosciences, has landed a $2 million grant from the Israel Innovation Authority for the development of its dry-AMD therapy, OpRegen. The Alameda, Calif.-based company’s OpRegen is an investigational therapy that delivers retinal pigment epithelial cells into the subretinal space to replace lost RPE cells. “This new […]
Medtech stories we missed: Feb. 10, 2017
From Glytec partnering to beat diabetes to Biolase, Gramercy Extremity Orthopedics and more getting FDA clearances, here are 7 recent medtech stories we missed this week, but were still worth mentioning. 1. BioTime proposes public offering of common stock Clinical-stage biotechnology company BioTech is intending to offer common stock shares in an underwritten public offering. BioTime focuses […]
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn